IN8bio reported that 14 patients treated with its repeat‑dose DeltEx Drug‑Resistant Immunotherapy (DeltEx DRI) achieved a median progression‑free survival of 13.0 months versus 6.6 months for 10 standard‑of‑care controls, and a median overall survival that has climbed to 17.2 months compared with 13.2 months for the control group. Several patients remained progression‑free for 1.4 to 4.6 years, underscoring the durability of the benefit.
The data were presented at the Society for Neuro‑Oncology Annual Meeting in November 2025 and announced on January 12 2026. The multi‑center study involved 14 patients receiving the gamma‑delta T‑cell therapy and 10 matched controls. No grade 3 or higher cytokine‑release syndrome events were observed, and the safety profile was well‑tolerated with no severe adverse events or dose‑limiting toxicities reported.
Historically, the Stupp protocol—radiotherapy with concomitant and adjuvant temozolomide—yields a median overall survival of 14–16 months and a median progression‑free survival of 6–9 months. The DeltEx DRI results exceed these benchmarks, suggesting a meaningful shift in the therapeutic landscape for newly diagnosed glioblastoma, a disease that has seen little innovation in over two decades.
These findings validate IN8bio’s gamma‑delta platform and strengthen the company’s position for future regulatory discussions, including the possibility of accelerated approval. The data also support ongoing partnership negotiations and reinforce the company’s strategy of developing off‑the‑shelf, chemotherapy‑resistant T‑cell therapies for high‑unmet‑need indications.
IN8bio’s recent private placement of up to $40.2 million in December 2025 is expected to extend its cash runway into the first half of 2027. The company currently holds roughly $30 million in cash, a figure that has been described as an existential risk for 2026. The positive clinical data may help attract additional funding or a strategic partnership to mitigate this risk.
CEO William Ho emphasized the significance of the results: “GBM is an extremely aggressive and devastating brain cancer, with a short median survival of only ~12 months and no meaningful innovation in over twenty years. The contrast between our repeat‑dose DeltEx DRI patients and the SOC controls treated at the same centers demonstrates a profound improvement. The increase in mPFS, particularly in the newly diagnosed GBM setting, is meaningful time for these patients.”
The durable survival gains reported by IN8bio could reshape treatment expectations for glioblastoma and position the company as a leader in the emerging field of gamma‑delta T‑cell therapies. The next steps will likely involve larger confirmatory studies, regulatory engagement, and the pursuit of strategic collaborations to accelerate the therapy’s path to market.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.